Damora Therapeutics Inc
galecto.comDamora Therapeutics Inc (NASDAQ: DMRA) is a clinical-stage biopharmaceutical company developing biological product candidates for undisclosed disease indications. The company has generated no revenue from product sales since inception, as disclosed in its 10-K filed March 19, 2026. Operations are funded entirely through equity financing, including Series B and Series C non-voting convertible preferred stock and common stock. Its pipeline consists of three named candidates: DMR-001, DMR-002, and DMR-003, all in preclinical or early clinical development as of December 31, 2025. The company relies on contract manufacturing organizations (CMOs) and contract research organizations (CROs) for manufacturing and clinical trial execution. With an accumulated deficit on its balance sheet and no near-term product revenue expected, Damora is a pre-commercial, capital-dependent biotech dependent on continued external financing to advance its programs through regulatory approval.
Products & Services
Three biological product candidates in development: DMR-001, DMR-002, and DMR-003. No products are approved or commercialized as of the 10-K filed March 19, 2026.
Revenue Model
No product revenue as of December 31, 2025. The company has generated no revenue from product sales since inception and funds operations through equity capital raises.
Customers & Markets
No commercial customers as of December 31, 2025. End markets are not specified in the filing excerpts provided.
Geographic Exposure
Primary regulatory focus on the United States (FDA). The company acknowledges subject to regulations in other jurisdictions but no specific geographic markets are identified in the filing excerpts.
Peers: Evaxion A/S Forward Pharma A/S IO Biotech Inc
Source: SEC 10-K, filed 2026-03-19
Financial Snapshot
Loading...
